Third, our study solely investigated the effects of GLP-1 RAs on KOA; emerging evidence from mechanistic studies and observed risk reductions in osteoarthritis at other anatomical sites collectively point to a potential systemic therapeutic effect of these agents (Baser et al., 2024a; Baser et al., 2024b). Here, GLP1R is linked to osteoarthritis.